Branching Scenario-Based Education in Coronary Artery Disease
The Effect of Branching Scenario-Based Education Delivered Through Virtual Reality and Tablet on Cardiovascular Disease Risk Awareness and Antiplatelet Medication Adherence in Patients With Coronary Artery Disease: A Randomized Controlled Trial
1 other identifier
interventional
54
1 country
1
Brief Summary
This randomized controlled trial aims to evaluate the effects of nurse-led branching scenario-based education delivered through virtual reality and tablet on cardiovascular disease risk awareness and adherence to antiplatelet medication in patients with coronary artery disease. Participants will be randomly assigned to a virtual reality education group, a tablet-based education group, or a control group receiving routine hospital education. Cardiovascular disease risk awareness and medication adherence will be assessed before and after the educational intervention and during follow-up.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Sep 2026
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
August 18, 2026
CompletedStudy Start
First participant enrolled
September 1, 2026
CompletedFirst Posted
Study publicly available on registry
September 17, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
April 1, 2027
September 17, 2026
September 1, 2026
3 months
August 18, 2026
September 11, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (3)
cardiovascular disease risk awareness assessment scale score
Change in cardiovascular disease risk awareness, assessed using the Turkish validated 22-item Cardiovascular Disease Risk Awareness Assessment Scale (CVD-RAAS). The knowledge domain score ranges from 0 to 8, with higher scores indicating higher knowledge about myocardial infarction and stroke. The total score for the 14-item Likert-type awareness subscales ranges from 14 to 56, with higher scores indicating greater awareness of cardiovascular disease risks, healthier dietary intentions, and higher readiness for behavioral change.
baseline and immediately after the educational intervention
medication adherence report scale score
Change in medication adherence, assessed using the Turkish validated 5-item Medication Adherence Report Scale (MARS-5). Each item is scored on a 5-point Likert scale (1 = always to 5 = never). Total scores range from 5 to 25, with higher scores indicating greater medication adherence.
Baseline, immediately after the intervention, and 3 months follow-up
Cardiovascular Disease Risk Awareness Assessed by the Cardiovascular Disease Risk Awareness Assessment Questionnaire
Cardiovascular disease risk awareness will be assessed using the Turkish version of the Cardiovascular Disease Risk Awareness Assessment Questionnaire (CDRAAQ), a 22-item instrument consisting of an 8-item knowledge section and three subscales: perceived risk of heart attack/stroke, healthy eating intentions, and perceived benefits and intentions to change. The knowledge items are scored as correct or incorrect, with each correct response receiving 1 point. The subscale items are rated on a 4-point Likert scale from 1 (strongly disagree) to 4 (strongly agree), with reverse scoring applied where appropriate. Higher scores indicate greater cardiovascular disease risk awareness, greater knowledge of heart attack and stroke, and greater readiness for health-related behavioral change.
Baseline, immediately after the intervention, and 3 months after the intervention.
Study Arms (3)
control group
NO INTERVENTIONparticipants in the control group receive routine clinical education.
virtual reality education
EXPERIMENTALParticipants in this arm will receive nurse-led branching scenario-based education on cardiovascular disease risk factors and medication adherence using a virtual reality headset.
Tablet Education
EXPERIMENTALParticipants in this arm will receive nurse-led branching scenario-based education on cardiovascular disease risk factors and medication adherence using a tablet and headphones.
Interventions
Participants will first complete a pre-test assessment. They will then receive nurse-led coronary artery disease education through an interactive, branching scenario-based educational program delivered using a virtual reality (VR) headset. The educational content includes visual, interactive, and scenario-based learning activities, with different learning pathways and feedback based on participants' choices. Following the educational intervention, participants will complete a post-test assessment.
Participants will first complete a pre-test assessment. They will then receive nurse-led coronary artery disease education through an interactive, branching scenario-based educational program delivered using a tablet. The educational content includes visual, interactive, and scenario-based learning activities, with different learning pathways and feedback based on participants' choices. Following the educational intervention, participants will complete a post-test assessment.
Eligibility Criteria
You may qualify if:
- Aged 18-65 years.
- Diagnosed with coronary artery disease.
- Newly initiated on antiplatelet therapy.
- Conscious and able to communicate.
- Physically and cognitively able to use a virtual reality headset.
- Able to read, write, and understand Turkish.
- Willing to provide written informed consent.
- Willing to participate in the education and follow-up process.
- Has not previously received education about coronary artery disease.
- Able to use a smartphone.
You may not qualify if:
- Cognitive impairment or mental illness preventing communication.
- Visual or hearing impairment preventing participation in the virtual reality education.
- Participation in another clinical study at the same time.
- Diagnosis of malignant disease.
- Bleeding disorder or active bleeding risk.
- Hospitalization within the previous 3 months due to acute myocardial infarction, stroke, or another serious cardiovascular event.
- Unable to understand the educational materials.
- Refusal to provide written informed consent.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Bolu Abant İzzet Baysal University
Bolu, Turkey (Türkiye)
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, OUTCOMES ASSESSOR
- Purpose
- HEALTH SERVICES RESEARCH
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Associate Professor
Study Record Dates
First Submitted
August 18, 2026
First Posted
September 17, 2026
Study Start
September 1, 2026
Primary Completion (Estimated)
December 1, 2026
Study Completion (Estimated)
April 1, 2027
Last Updated
September 17, 2026
Record last verified: 2026-09
Data Sharing
- IPD Sharing
- Will not share
for the protection of personal data